What route should I use for AOD-9604?

AOD-9604 is delivered by subq/oral (capsule, lower bioavailability). Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

How does AOD-9604 map to the hallmarks of aging?

AOD-9604's longevity relevance maps to specific hallmarks based on its mechanism. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

What is the regulatory status of AOD-9604?

AOD-9604 regulatory status: Unapproved (Research Only) in the United States; WADA status not on prohibited list (verify annually); research level phase iib completed; not commercialised. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Should I cycle AOD-9604?

Standard cycle for AOD-9604 is 8–12 weeks of 1x daily am 300-500 mcg dosing via subq/oral (capsule, lower bioavailability), followed by a 4 week complete off-period. The off-period is calibrated to AOD-9604's ~30 min IV; longer SubQ half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ AOD-9604

AOD-9604

Longevity

For users tracking biological age and healthspan-relevant biomarkers, AOD-9604 sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). A modified human growth hormone fragment studied for fat metabolism without the growth-promoting side effects of full GH. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

Telomere SupportMitochondrial BiogenesisNAD+ MetabolismProteostasismTOR Modulation

Key Takeaways

Longevity lens: AOD-9604 maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 300-500 mcg 1x daily am dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for AOD-9604.

Mapping to the hallmarks of aging

AOD-9604's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Cellular reprogramming and gene expression

Where AOD-9604 has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after AOD-9604 cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Longevity / Hallmarks of Aging Applications

Telomere Support

For telomere support as a longevity-relevant endpoint, AOD-9604 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

NAD+ Metabolism

NAD+ Metabolism maps to one of the hallmarks of aging and is one of the dimensions on which AOD-9604 is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Senescence Modulation

AOD-9604's contribution to senescence modulation as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Cellular Reprogramming

For cellular reprogramming as a longevity-relevant endpoint, AOD-9604 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	300-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	180-500 mcg	4–6 weeks initial cycle
Longevity focus	SubQ	300-500 mcg	1x daily AM
Maintenance phase	SubQ	210-500 mcg	Ongoing with periodic pauses

Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

AOD-9604 + Epithalon: Identified by Khavinson in St. Pairs naturally with AOD-9604's mechanism in longevity / hallmarks of aging protocols.
AOD-9604 + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with AOD-9604's mechanism in longevity / hallmarks of aging protocols.
AOD-9604 + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with AOD-9604's mechanism in longevity / hallmarks of aging protocols.
AOD-9604 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with AOD-9604's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list (verify annually) FDA: Unapproved (Research Only) Research: Phase IIb completed; not commercialised

No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).

Lens-specific safety considerations for longevity / hallmarks of aging use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Effects of an oral lipolytic peptide (AOD9604) on body composition in obese subjects

PMID 12972433

Supporting

AOD9604 and obesity: clinical findings

PMID 19077115

AOD-9604 vs Related Peptides

Compound	Profile	Onset	Best For
AOD-9604	GH fragment	~30 min IV; longer SubQ	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Does AOD-9604 interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. AOD-9604 fits this framework with cycle lengths typical for its compound class.

When in life should I start AOD-9604?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

What should I look for in AOD-9604 sourcing and quality?

Acceptable AOD-9604 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1815.1 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How should AOD-9604 be stored and reconstituted?

Lyophilised AOD-9604 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Clinical Protocol

Start a AOD-9604 Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified AOD-9604 and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 1815.1 Da
Sequence length: 16 aa
Half-life: ~30 min IV; longer SubQ
WADA: Not on prohibited list (verify annually)
FDA: Unapproved (Research Only)
Research: Phase IIb completed; not commercialised

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for AOD-9604

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised